Show simple item record

dc.contributor.authorCoughlan, C
dc.contributor.authorFitzgerald, J
dc.contributor.authorMilne, P
dc.contributor.authorWingfield, M
dc.date.accessioned2012-03-30T14:01:00Z
dc.date.available2012-03-30T14:01:00Z
dc.date.issued2010-05
dc.identifier.citationIs it safe to prescribe clomiphene citrate without ultrasound monitoring facilities? 2010, 30 (4):393-6 J Obstet Gynaecol
dc.identifier.issn1364-6893
dc.identifier.pmid20455725
dc.identifier.doi10.3109/01443611003646280
dc.identifier.urihttp://hdl.handle.net/10147/217195
dc.description.abstractThe majority of triplet and higher order multiple pregnancies now result from ovulation induction/superovulation rather than in vitro fertilisation. However, clomiphene citrate is still widely prescribed by gynaecologists and general practitioners who do not have access to ultrasound monitoring. The objective of our study was to determine the prevalence of multifollicular development with different doses of clomiphene citrate. A retrospective review of transvaginal ultrasound monitoring of 425 cycles in 182 women receiving clomiphene citrate from January 2002 to December 2003, was studied. Three or more follicles of >or= 14 mm were identified in 58 cycles (14%). Patients received 50 mg of clomiphene citrate in 52 of these 58 cycles and 25 mg in the remaining six. One patient was noted to have developed five follicles and 10 patients developed four follicles. One patient developed six follicles, despite receiving only 25 mg clomiphene citrate daily. It was concluded that a significant number of women (14%) developed three or more follicles, despite receiving low doses of clomiphene citrate.
dc.language.isoen
dc.rightsArchived with thanks to Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecologyen_GB
dc.subject.meshClomiphene
dc.subject.meshFemale
dc.subject.meshFertility Agents, Female
dc.subject.meshHumans
dc.subject.meshPregnancy
dc.subject.meshRetrospective Studies
dc.subject.meshSuperovulation
dc.subject.meshUltrasonography
dc.titleIs it safe to prescribe clomiphene citrate without ultrasound monitoring facilities?en_GB
dc.contributor.departmentMerrion Fertility Clinic, National Maternity Hospital, Dublin, Republic of Ireland. C.J.Coughlan@sheffield.ac.uk
dc.identifier.journalJournal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
dc.type.qualificationlevelN/Aen
cr.approval.ethicalN/Aen
dc.description.provinceLeinsteren
dc.description.provinceLeinster
html.description.abstractThe majority of triplet and higher order multiple pregnancies now result from ovulation induction/superovulation rather than in vitro fertilisation. However, clomiphene citrate is still widely prescribed by gynaecologists and general practitioners who do not have access to ultrasound monitoring. The objective of our study was to determine the prevalence of multifollicular development with different doses of clomiphene citrate. A retrospective review of transvaginal ultrasound monitoring of 425 cycles in 182 women receiving clomiphene citrate from January 2002 to December 2003, was studied. Three or more follicles of >or= 14 mm were identified in 58 cycles (14%). Patients received 50 mg of clomiphene citrate in 52 of these 58 cycles and 25 mg in the remaining six. One patient was noted to have developed five follicles and 10 patients developed four follicles. One patient developed six follicles, despite receiving only 25 mg clomiphene citrate daily. It was concluded that a significant number of women (14%) developed three or more follicles, despite receiving low doses of clomiphene citrate.


This item appears in the following Collection(s)

Show simple item record